A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
← catalyst calendarSponsored by Avalo Therapeutics, Inc. (industry) · AVTX — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
253actual
Sites
89
Countries
Australia, Bulgaria, Canada +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-16 | actual | When the study began enrolling |
| Primary completion | 2026-02-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-17 | actual | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hidradenitis Suppurativa
Interventions
- Drug: AVTX-009 Regimen 1
- Drug: AVTX-009 Regimen 2
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFProportion of patients achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)
measured At Week 16
Permalink · AVTX's whole pipeline · Catalyst calendar · Every registered study · What changed